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Abstract
 .Urokinase-type plasminogen activator uPA initiates a proteolytic cascade with which invasive cells eliminate barriers to
movement. The signaling pathways regulating uPA production in tumor cells remain unclear. We first studied the effects of
 .  .n-butanol, a phospholipase D PLD and protein kinase C PKC inhibitor, on the production of uPA in murine mammary
adenocarcinoma cells. Tumor cell monolayers treated during 24 h with 0.3% vrv n-butanol, secreted 45–50% less uPA to
 .the culture medium than control monolayers P-0.001 as determined by radial caseinolysis, zymography and western
blot. This inhibition occurred also with 5-h treatments and remained up to 5 h after the removal of the alcohol. Treatment
 .with the phorbol ester PMA or with EGF, strongly increased uPA production P-0.001 . Interestingly, a mild inhibition of
uPA production was observed when PMA stimulation was assayed in cotreatments with n-butanol. In contrast EGF was
 .unable to reverse the inhibition induced by n-butanol. H7 significantly inhibited uPA activity P-0.001 secreted to the
culture media. Furthermore, phosphatidic acid significantly stimulated uPA production meanwhile propranolol, which
blocks phosphatidic acid availability, reduced it, suggesting a main regulatory role for this intermediary metabolite. These
results suggest for the first time that uPA production is regulated by PLD and PKC signal transduction pathways in murine
mammary adenocarcinoma cells.
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1. Introduction
Metastasis, the formation of new tumor foci in
distant organ sites, is the last and most damaging step
of tumor progression. Tumor cells, depart from the
primary tumor, reach distant organs and develop
tumor metastasis, through a multistep process. Some
of these steps include intravasation, blood-borne dis-
semination, extravasation, invasion and settlement in
w xnew organ sites 1 . Proteolytic enzymes such as
metalloproteinases, serine-proteases and cathepsins
are key molecules in normal or pathological events
such as tissue remodeling, wound healing, inflamma-
w xtion and tumor development 2 . The overproduction
by tumor cells of proteolytic enzymes such as uroki-
 .nase-type plasminogen activator uPA , a serine pro-
tease that activates plasminogen to plasmin and en-
 .ables the extracellular matrix ECM degradation, has
been extensively described as one of the major con-
w xtributors to tumor cell invasive phenotype 3 . In
addition, uPA can also directly degrade some of the
w xECM proteins 4 . uPA receptor has also been de-
scribed to contribute to cell invasion by focusing
w xECM degradation 4 .
Several workers have shown that uPA expression
by tumor cells is upregulated by growth factors such
w xas EGF or IGF 5,6 , ECM proteins such as laminin
w x7 or even by the procoagulant enzyme thrombin
w xthrough a receptor-dependent mechanism 8 . Re-
w xcently, Wang et al. 9 have reported that phorbol-
 .12-myristate 13-acetate PMA can induce the ex-
pression of uPA, suggesting that the expression of
uPA must be controlled by precise mechanisms.
 .Phosphatidylcholine PC breakdown by phospho-
lipase D is a widespread event which has led to the
conviction that it plays a key role in cell regulation
w x10 . Recent evidence indicates that the major source
 .of diacylglycerol DAG is a consequence of the
w xactivation of PLD 10 . This occurs when PLD-de-
pendent PC hydrolysis releases choline and phospha-
tidic acid and the action of phosphatidic acid phos-
 .phohydrolases PAP on phosphatidic acid results in
w xthe production of DAG 11 . Furthermore DAG has
been extensively described as the endogenous activa-
 . w xtor of protein kinase C PKC 12 . Several reports
have also shown that only PLD can synthesize phos-
phatidylalcohols through a transphosphatidylation re-
action in which the phosphatidyl group of phospho-
lipids is transferred to a primary alcohol such as
w xn-butanol 13 . This reaction generates a stable and
nonhydrolyzable molecule, after phosphatidylcholine
w xbreakdown by PLD 14,15 . In addition, this reaction
results in the inhibition of phosphatidic acid produc-
tion and subsequently decreases the production of
DAG which eventually would be followed by a lower
w x w xactivation of PKC 16 . Recently, Slater et. al. 12
have demonstrated that n-butanol can also inhibit the
activation of PKC mediated by the commonly used
analogues of DAG, 12-O-tetradecanoylphorbol-13-
 .  .acetate TPA , 1-oleoyl-2-acetylglycerol OAG and
 .1,2-dioleoylglycerol DOG , in reconstituted mem-
brane assays by specifically acting on the regulatory
w xsubunit of the enzyme 17 .
It has been widely reported that uPA is a key
enzyme in the proteolytic cascade involved in the
w xinvasion and metastatic process 4 . However, it has
not been established which second messengers and
signaling effector proteins are involved in the signal
transduction pathways that regulate uPA expression
in tumor cells. We have previously reported that
secreted uPA and membrane-bound uPA activities of
murine mammary adenocarcinoma cells could be re-
w xduced by a short term n-butanol treatment 18 . This
inhibition persisted over 72 h after treatment, suggest-
w xing the blockade of specific regulatory signals 18 .
Since the development of metastasis is responsible
for the majority of cancer related mortalities and uPA
is one of the major contributors of the protelolytic
w xcascade involved in metastasis formation 1 , under-
standing how tumor or normal cells regulate uPA
production is of extreme importance.
The aim of this work is to analyze whether PLD
andror PKC-dependent signaling pathways are in-
volved in the regulation of uPA production. We also
attempted to determine if this regulation is related to
endogenous-, agonist- or growth factor-dependent
signals. Here we provide data indicating that PLD
and PKC dependent pathways appear to be critically
involved in the upregulation of uPA production by
murine mammary tumor cells.
2. Materials and methods
2.1. Drugs, reagents and antibodies
EDTA and n-butanol were purchased from Merck
 .Co. Minimal Essential Medium MEM 410–1500
( )J.A. Aguirre Ghiso et al.rBiochimica et Biophysica Acta 1356 1997 171–184 173
and D-MEM lacking methionine were obtained from
Gibco BRL Laboratories. PMA, EGF, phosphatidic
acid, H7, propranolol, trypsin, amiloride and
dimethylsulfoxide were purchased from Sigma
Chemical Co. Anti-murine uPA antibody was kindly
provided by Dr. G. H-Hansen Copenhagen, Den-
.mark . Biotinylated anti-rabbit IgG polyclonal anti-
body and streptavidin-alkaline-phosphatase were pur-
chased from Gibco Laboratories. Urokinase was
kindly provided by Serono Laboratories. Plasmino-
gen was purchased from Chromogenics. Nitrocellu-
lose membranes were purchased from Bio Rad.
w35 xS methionine was purchased from Du Pont, NEN
Products.
2.2. Cells and culture conditions
The LM3 cell line was established in our labora-
tory from primary cultures of a BALBrc trans-
w xplantable mammary adenocarcinoma M3 19 . F3II
cell line was established by clonal dilution from M3
w xprimary cell cultures 20 . These cell lines constitu-
tively produce high levels of uPA but none of tissue-
 . w xtype plasminogen activator tPA 20,21 . LM3 and
F3II cells from passages 100 to 140 and 60 to 100
respectively, were maintained in MEM 410–1500,
supplemented with 5% heat-inactivated fetal bovine
 .serum FBS , 2 mM L-glutamine and 80 mgrml
gentamicin. Cells were routinely passaged using
0.25% trypsin containing 0.02% EDTA. In all experi-
ments, cells were seeded on 6 or 24 plastic multiwell
 . 5plates Corning at a concentration of 2.5=10 and
1=104 cellsrwell respectively and grown to semi-
confluent monolayers in the conditions described
above. Cell lines were found to be free of My-
coplasma.
2.3. Preparation of conditioned media
Secreted uPA activity was investigated in condi-
 .  .tioned media CM 21 . Briefly, semiconfluent LM3
cells were extensively washed in phosphate buffer
 .saline PBS to eliminate serum traces. Serum-free
MEM plus the tested drugs were added and incuba-
tion was continued for different time lapses see
.results . Conditioned media were individually har-
vested, the remaining monolayers were trypsinized
and hemocytometer cell counting or protein content
determinations were performed. Conditioned media
 .samples were centrifuged 600=g , aliquoted and
stored at y408C and used only once after thawing.
2.4. n-Butanol treatments
To establish the maximal inhibition of uPA pro-
duction cell monolayers were incubated 24 h with
 .increasing amounts of n-butanol 0.3–1% vrv or
 .control treatment MEMrPBS 0.3–1% vrv . In or-
der to determine whether the effect on uPA produc-
tion persisted after n-butanol removal, n-butanol pre-
treated cell monolayers were washed with PBS and
incubated for 3 h with plain MEM medium. Also, to
study if the effect of n-butanol on uPA production
was dependent on cellular enzymatic activity, tumor
cells were incubated for 5 h at 378C or 48C with
 .n-butanol 0.3% vrv washed and further incubated
for 5 to 14-h periods in the absence of the alcohol. In
all experiments uPA activity present in the condi-
tioned media was quantified by radial caseinolysis
and characterized by zymography and western blot.
In order to determine if n-butanol had a direct action
on catalytic uPA activity, curves with the purified
 .human standard urokinase 0.2–100 IUrml and
 .murine uPA from mouse urine 5–20 IUrml were
assayed in presence or absence of n-butanol 0.3%
.vrv or control treatment.
2.5. Zymography and radial caseinolysis
SDS-polyacrylamide gel electrophoresis were per-
w xformed as described by Laemmli 22 using 10%
separating and 4% stacking gels. Gels were washed
with 2.5% Triton X-100 and incubated on the surface
of a plasminogen-rich casein-agarose underlay, as
w xdescribed 18 . To confirm uPA activity present in
zymograms, plasminogen-casein-agarose underlays
were prepared with an anticatalytic anti-murine uPA
antibody, amiloride 1 mM or without plasminogen.
uPA activity was quantified by a radial caseinolysis
w xassay 23 , using plasminogen-rich casein-agarose
plates. Secreted uPA activity was referenced to a
standard urokinase curve and normalized to 106 cells
and to a 24-h incubation period, unless otherwise
w xindicated 21 .
2.6. Labeling of protein synthesis products with
[35 ]S methionine
To study the effect of n-butanol on de novo
protein synthesis, subconfluent monolayers of LM3
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cells were washed with PBS and incubated for 30
 .min with MEM lacking methionine -MetrMEM .
Medium was then replaced with MEM containing
w35 x125 mCi of S methionine per ml of medium in the
 .presence or absence of 0.3% vrv n-butanol. After 6
h LM3 cell monolayers were washed and cell lysates
were prepared using a 1% Triton X-100rPBS solu-
tion. Cell lysates were electrophoresed in a 9% SDS-
PAGE gel. Dried gels were exposed for 24 h at
 .y708C with XAR-5 film Eastman Kodak .
2.7. Western blot and densitometry
Cell monolayers were cultured with MEM in the
presence or absence of the tested drugs. Conditioned
media were collected, electrophoresed in a 9% SDS-
w xPAGE gel and transferred to nitrocellulose 24 . The
filter was probed with or without rabbit IgG anti-
murine uPA antibody and revealed with a biotyni-
lated-IgG anti-rabbit-alkaline-phosphatase conjugated
w xpolyclonal antibody 24 . The protein bands were
quantitated with a Molecular AnalysterPC Densito-
 .meter Model GS-670 Bio-Rad USA and analyzed
with the Image Analysis Software for Model GS-670
 .Bio-Rad, USA .
2.8. PMA and H7 treatments
LM3 cells were treated with PMA 0.1 nM–500
.  .nM or H7 0.1–1000 uM to determine the dose
response-curve for uPA expression. The same range
of concentrations for PMA were tested in the pres-
 .ence of n-butanol 0.3%vrv . PMA was dissolved in
DMSO. Final work concentrations of DMSO were
lower than 0.01%. All the corresponding controls
were performed in the presence of the same concen-
tration of DMSO. Cell viability was determined to be
100% up to 0.5% DMSO based on trypan blue dye
 .exclusion assay data not shown .
2.9. EGF treatments
 .EGF 5–50 ngrml was added during 24 h to
subconfluent cell monolayers in the presence or ab-
sence of n-butanol 0.3%vrv. Also, F3II subconfluent
cell monolayers were treated during 24 h with n-
 .butanol 0.3% vrv . After this treatment period, cell
monolayers were washed with PBS and either control
treatment or MEM with 20 ngrml of EGF were
added and CM harvested in sequential periods of 4 h.
2.10. Phosphatidic acid and propranolol treatments
 4L a-phosphatidic acid 0.1–10 ngrml, dissolved
.  .in DMSO or DL-propranolol 0.1–500 uM were
also assayed for their effect on uPA production. As
assayed by trypan blue exclusion test, propranolol
concentrations up to 200 uM and phosphatidic acid
did not show cytotoxic effects on cell monolayers.
 .High doses of propranolol 300–500 mM in 6–24-h
incubation periods showed a mild toxicity on cell
monolayers.
3. Results
3.1. n-Butanol inhibition of uPA production
The alcohol n-butanol can inhibit PLD activity by
the synthesis of non-hydrolyzable phosphatidylbu-
 .tanol PB blocking the down stream production of
w xphosphatidic acid and DAG 13,15 . We tried to
establish if the treatment of cell monolayers with
different doses of n-butanol could inhibit uPA pro-
duction and if the effect remained after the alcohol
removal. The treatment of cell monolayers with n-
butanol showed an inhibitory effect on constitutively
secreted uPA activity. After 3 h of n-butanol wash-
out, a significant dose-dependent inhibitory effect
was still observed, suggesting that the post-treatment
inhibition could be due to a cellular dependent mech-
 .anism Fig. 1A .
Concentrations of n-butanol up to 1% vrv showed
no toxic effects over a 24-h period of incubation on
 .cell monolayers. A concentration of 0.3% vrv, IC50
of n-butanol was chosen to perform further assays
 .Fig. 1B . Under these conditions no cytotoxicity or
decrease in cell viability as assessed by trypan blue
exclusion were observed. However, further studies
were performed to discard a transient mild cytotoxic-
ity of n-butanol, which could be disrupting cellular
metabolism and inducing a general protein synthesis
inhibition. An assay of de novo protein synthesis
w35 xusing S methionine showed no difference in total
protein synthesis between LM3 cells treated or non-
 .  .treated for 6 h with n-butanol 0.3% vrv Fig. 1C .
( )J.A. Aguirre Ghiso et al.rBiochimica et Biophysica Acta 1356 1997 171–184 175
LM3 cell monolayers treated with n-butanol 0.3%
.vrv or control treatment, showed no differences in
mitochondrial metabolism, employing a chemosensi-
tivity assay which measures the cellular conversion
of the tetrazolium salt, MTS, into a formazan Pro-
.  .mega Corporation data not shown . In addition
LM3 cells treated for 24 h with n-butanol 0.3%
.vrv showed no modulation in their plating effi-
 .Fig. 1. Effect of n-butanol on constitutive uPA production by LM3 cells. A Inhibition of uPA secreted activity by increasing doses of
 .  .n-butanol: inhibition of a 24-h treatment empty squares and the remaining inhibition 3 h after n-butanol wash-out filled triangles ; SD
 .  .was less than 10% for each point. B Effect of 0.3% vrv n-butanol on LM3 cells uPA production during a 24-h treatment. uPA
6  .  .  .activity is expressed in IUr10 cellsr24h for control or treated groups. Inset Effect of n-butanol 0.3% vrv filled triangle or control
 .  .  .treatment empty squares on the catalytic activity of purified urokinase standard. C Autorradiography inverse image showing de novo
 .  .  .protein synthesis in lysates of LM3 cells treated for 6 h with control treatment lanes a or c or 0.3% vrv n-butanol lanes b or d ; lanes
 .c and d correspond to a duplicate independent experiment; MW, molecular weight markers. D Anti-uPA Western blot and densitometric
 .  .  .  .analysis of CM from LM3 cells treated with control treatment lane 1 or 0.3% vrv n-butanol lane 2 . E Zymographic identification
 .  .  .of uPA activity present in control CM lane 1 by specific inhibition with amiloride 1 mM lane 2 and anti-uPA anti-catalytic antibody
 . ) ))lane 3 . P-0.001 and P-0.01 as determined by Student’s t test. Determinations for each treatment were performed at least by
triplicate and figures are representative of three independent experiments.
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ciency compared to control treated cells data not
.shown . These results indicate that the inhibitory
effect of n-butanol on uPA production is not due to a
cytotoxic effect on cellular metabolism, which could
induce a general inhibition of protein synthesis or
disruption of cellular metabolism leading to down
modulation of biochemical and biological cellular
events.
Since n-butanol could be directly modifying uroki-
nase catalytic activity, purified human and murine
urokinase activity was assayed with or without n-
 .  .butanol 0.3% vrv . Fig. 1B inset shows that there
was neither an inhibitory nor a stimulatory effect of
n-butanol on urokinase catalytic activity.
Western blot with anti murine uPA antibody con-
firmed and correlated the decrease in constitutive
uPA secreted activity with a lower uPA antigen
 .expression Fig. 1D . Zymographic assays showed
that cell monolayers produced a plasminogen activa-
tor activity corresponding to a main band of 48 kDa
 .Fig. 1E . This activity was completely abolished by
anti-catalytic antibodies to murine uPA and by
amiloride, confirming uPA identity and previous re-
 .  .sults 21,24 Fig. 1E . Plasminogen-independent pro-
 .tease activity was not detected data not shown .
3.2. n-Butanol inhibition of uPA production: time-
course and temperature effects
If the inhibitory effect observed on constitutive
uPA secreted activity after n-butanol removal was
Fig. 2. Inhibition of uPA production by n-butanol: Time and
 .temperature dependency. A Inhibition of uPA production during
a 5-h treatment period, step A, and during a 5 and 14-h period
 .after the alcohol removal, step B; control treatment empty bars
 .  .and n-butanol treatment hatched bars . B Western blot and
densitometric analysis of uPA secreted antigen present in CM of
LM3 cells treated with control treatment empty bars; lane 1, 3,
.  .5 or n-butanol 0.3% hatched bars; lane 2, 4, 6 during the time
 .course inhibition assay. C Inhibition of uPA production during
a 5-h treatment period at 48C, step A, and during a 5 and 14-h
period after n-butanol wash-out at 378C, step B; control treatment
 .  .empty bars and n-butanol treatment hatched bars . In these
experiments, to compare results between 5-h and 14-h incuba-
tions, uPA activity was normalized to IU per 106 cells per h.
) P -0.001 as determined by Student’s t test. Determinations
for each treatment were performed at least by triplicate and
figures are representative of three independent experiment. SD in
al experiments was less than 5%.
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 .  .Fig. 3. Effect of PMA on uPA production. A PMA-dose dependent induced stimulation of uPA production in LM3 cells. B Western
 .blot and densitometric analysis of uPA antigen present in CM of LM3 cells treated with control treatment hatched bar and lane 1
 .  .  .n-butanol 0.3% empty bar and lane 2 , PMA 5 nM filled bar and lane 3 , PMA 5 nMrn-butanol 0.3% heavy hatched bar and lane 4 .
 .  . C Zymography of uPA and not tPA activity present in CM of tumor cells treated with control treatment lane 1 , n-butanol 0.3% lane
.  .  .  .  . 2 and PMA 5nM lane 3 . D uPA activity present in CM of control hatched bars , n-butanol 0.3% empty bars , PMA 5 nM filled
.  .  .bars or PMA 5 nMrn-butanol 0.3% heavy hatched bars LM3 cells treated during 24 h. E Inhibition of n-butanol 0.3% on dose
dependent stimulation by PMA of uPA production in LM3 cells PMA treatment, filled triangles and n-butanolrPMA treatment, empty
.squares ; dotted line shows control values for stimulation and full line shows the lower level of inhibition obtained with n-butanol 0.3%
vrv. ) P-0.001 as determined by t-Students test. Data are expressed as mean and SD of at least triplicate determinations and figures are
representative of three independent experiments. SD was less than 10% in all experiments.
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the result of the previous synthesis of the non-hydro-
lyzable product PB, the effect should remain along a
determined period of time. Further, an enzyme activ-
ity-dependent effect participating in the inhibitory
process would be abolished if the enzymatic activity
is blocked. As observed in Fig. 2A–B, secreted uPA
antigen and activity were inhibited by a short 5-h
treatment at 378C. The inhibition remained over at
least other 5 h after n-butanol wash-out but was
completely reversed 14 h after the alcohol removal.
This same time-course assay showed no differences
between the mitocondrial metabolic activity of LM3
 .cells treated with n-butanol 0.3% vrv or control
treatment measured with a chemosensitivity assay
 .Promega Corporation indicating a specific modula-
 .tion of uPA production data not shown . In contrast,
when the incubation with n-butanol was performed at
48C, no inhibitory effect could be observed after
 .n-butanol wash-out Fig. 2C . These results show a
time- and temperature-dependent effect for the main-
tenance of the n-butanol-mediated inhibition. Al-
though uPA secretion at 48C was very low, measur-
able activity could be detected.
3.3. PMA stimulation and H7 inhibition of uPA pro-
duction
Cell monolayers treated for 24 h with increasing
doses of PMA showed a significant enhancement of
uPA secreted activity, reaching a maximum level
 .over a concentration of 5 nM Fig. 3A as determined
by enzyme activity and zymography. No differences
 .in the stimulation of uPA production by PMA 5 nM
were observed between 12 h treatments and those of
24 h indicating that, at this concentration PMA was
not exerting a depletory effect on PKC data not
.shown . This same concentration also induced an
important increase in secreted uPA antigen as deter-
 .mined by Western blot Fig. 3B . PMA could be
stimulating tPA expression instead of uPA, but zymo-
grams revealed that uPA production and not tPA, was
 .stimulated Fig. 3C . Western blot and activity assays
showed that n-butanol-mediated inhibition of uPA
could be partially but significantly reversed by the
 .coincubation with 5 nM PMA Fig. 3D . However, in
Fig. 3E it can be clearly seen that n-butanol partially
blocked PMA stimulated expression of uPA. It has
been described that phorbol esters can reverse in a
Fig. 4. Dose-dependent inhibition of uPA production by H7 in
LM3 cells during a 24-h assay. Toxicity was not observed with
high doses of H7. Horizontal lines indicate the range of control
values. ) P -0.001 as determined by Student’s t test. Data are
expressed as mean and SD of at least triplicate determinations
and representative of duplicate independent experiments. SD in
all experiments was less than 10%.
dose dependent but not competitive manner, n-butanol
w xinhibition on PKC regulatory subunit 12,17 . Al-
though n-butanol could reduce the stimulatory effect
of PMA on the production of uPA, PMA could still
significantly increase uPA production even in pres-
ence of the alcohol, demonstrating that it could re-
 .verse partially n-butanol inhibition Fig. 3E .
PMA over 100 nM showed a less enhancing effect
than lower doses. This could be due to the PKC-de-
pleting capacity of PMA at these concentrations,
considering that the activity measured was accumu-
lated during 24 h in the media. In addition when
these concentrations were assayed in presence of
n-butanol, a clear and significant inhibitory effect of
uPA production was observed. In order to confirm
PKC involvement in the regulation of uPA produc-
tion, we employed H7, the specific inhibitor of con-
ventional and atypical isoforms of PKC, which has
been described to interact with the catalytic domain
of the enzyme and compete with ATP for binding to
w xPKC 25 . Fig. 4 shows that H7 could inhibit consti-
tutive uPA secreted activity upon treatment of cell
monolayers during a 24-h period with an IC50 of 20
mM.
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3.4. EGF stimulated production of uPA can be inhib-
ited by n-butanol
EGF exerts its effects via a tyrosine kinase recep-
w xtor coupled to PLDrPKC signaling pathways 5 .
Here we show that EGF stimulated, in a dose depen-
dent manner, the production of uPA in LM3 cell
 .monolayers Fig. 5A . When LM3 celI monolayers
were coincubated with both, EGF 20 ngrml and
 .n-butanol 0.3% vrv , the EGF-mediated stimulation
of uPA secreted activity was completely abolished
 .Fig. 5B . Similar results were observed for F3II cell
 .monolayers data not shown . Further, EGF was added
to F3II monolayers which had been preincubated for
 .24 h with n-butanol 0.3% vrv or control treatment
and washed. The addition of EGF to these monolay-
ers could not reverse the post-treatment inhibitory
effect of n-butanol over at least an 8-h period, but
EGF added to monolayers not pretreated with the
alcohol showed an increase in uPA secreted activity
 .Fig. 5C .
3.5. Phosphatidic acid functions as a regulatory
metabolite on uPA production
Phosphatidic acid is the substrate of PAP for the
synthesis of DAG. Since n-butanol could be blocking
the synthesis of this intermediate metabolite, we tested
whether phosphatidic acid could directly enhance
uPA production in tumor cells. Phosphatidic acid
micelles added to cell monolayers resulted in an
increase of secreted uPA activity with a clear dose
dependent effect, between 10 and 1000 ngrml Fig.
.6A . Interestingly, phosphatidic acid concentrations
over 1 mgrml inhibited uPA production. These re-
sults would suggest that phosphatidic acid per se or
perhaps converted to DAG or LPA could be involved
in the pathway that regulates uPA production.
 .Fig. 5. Effect of EGF and n-butanol on uPA production. A
Dose-response curve for EGF-induced production of uPA in LM3
 .cells for a 24-h assay. B uPA production by LM3 cells treated
 . with control treatment hatched bars , n-butanol 0.3% empty
.  .  .bars , EGF 20 ngrml filled bars or EGF 20 ngrml rn-butanol
 .  .0.3% heavy hatched bars . C n-butanol inhibition of uPA
production in F3II cells treated during 20 h, step A. Cell mono-
layers were washed 3 times and further treated with 20 ngrml of
EGF or control treatment in absence of n-butanol for periods of
4h after the alcohol removal, step B; to compare results between
the different times of incubation activity values were divided by
the total time to obtain the activity per h and results are expressed
as % of control. ) P -0.001 as determined by Student’s t test.
Data are expressed as mean and SD of at least triplicate determi-
nations of a representative independent experiment performed by
triplicate. SD in al experiments was less than 10%.
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Fig. 6. Effect of phosphatidic acid and propranolol on uPA
 .production. A Induction by PC breakdown product, phospha-
tidic acid, of uPA secreted activity to the CM for 24 h in LM3
cells; horizontal lines indicate the range of control values. No
toxicity was observed with phosphatidic acid treatment in any of
 .the concentrations used. B Dose dependent inhibition of uPA
production by propranolol in LM3 cells. ) P -0.001 as deter-
mined by t-Students test. Data are expressed as mean and SD of
at least duplicate determinations of a representative independent
experiment performed by duplicate.
Phosphatidic acid can be converted to the lipid
w xsecond messenger DAG 11 . If uPA production de-
pended on a PKC-mediated pathway which, in turn,
is activated by DAG originating from PC breakdown
and PAP activity, a decrease of available phospha-
tidic acid for this last enzyme should reduce uPA
production. In the following experiment, propranolol,
described to interact with phosphatidic acid, blocking
its availability as a substrate for further reactions,
exhibited a dose dependent inhibition of uPA with a
significant reduction of uPA production over 100
mM. This result supports the hypothesis that phos-
phatidic acid, perhaps converted to DAG, plays a
primary role in the regulation of uPA production
 .Fig. 6B .
4. Discussion
The overproduction of urokinase by tumor cells
has been correlated with the metastatic and invasive
phenotype in numerous human neoplasias and experi-
w xmental tumor models 8 . Although it has been de-
w xscribed that some growth factors 5 and specific
w xagonist molecules induce uPA expression 9 , the
signaling pathways that regulate urokinase production
in tumor cells are not fully understood.
The present results show for the first time that
constitutive-, agonist- and growth factor-induced pro-
duction of uPA in tumor cells involve the PLD and
PKC regulatory signaling pathway. The findings that
indicate the causal relationship between these events
are supported by the following results. We observed a
reduction of constitutive uPA production in the pres-
ence of increasing amounts of n-butanol. This fact
supports the hypothesis that n-butanol, acting as an
alternate substrate for PLD, could be attenuating the
production of phosphatidic acid and so inhibiting the
down-stream production of DAG. Since phosphatidy-
lalcohols are stable nonhydrolyzable molecules after
w xsynthesis 14,15 , their overproduction could tem-
porarily deplete cell membranes of phosphatidic acid,
thus inhibiting the synthesis of DAG. However, the
inhibitory effect would remain for a determined pe-
riod of time and would finally disappear as a result of
de novo synthesis of PC. Our results show that
increasing amounts of n-butanol during pre-treatment
correlate with a longer lasting maintenance of the
decreased uPA expression after the removal of the
alcohol. This result could be explained by the fact
that increasing amounts of PB in the cell membrane,
which in turn depend on the concentration of n-
butanol used in the pre-treatment, consequently lower
the amount of available phosphatidic acid and shut
down the downstream reactions. It was also observed
that after several hours post-treatment the inhibition
was spontaneously reversed. The fact that the cat-
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alytic activity of purified uPA was not affected by the
presence of n-butanol indicates that the inhibition is
indeed an effect with cellular dependency. The con-
centration of n-butanol used in these assays has been
reported to inhibit PLD-dependent signals in other
w xexperimental models 26 . Further, PLD is the only
phopholipase able to transfer the phosphatidyl group
of phosphatidic acid to primary alcohols as n-butanol
w x13 , so it is very unlikely that the observed activity
w xwas dependent of PLC 10 . In addition we have
demonstrated that if a 5-h incubation with n-butanol
is performed at low temperature instead of the
physiological one, the postreatment inhibition is abol-
ished. This result clearly involves the participation of
a cellular enzymatic-dependent activity for the post-
treatment inhibition that could be possibly attributed
to PLD.
An interesting finding is that, even at low tempera-
tures, a measurable secretion of uPA could be de-
tected in both, n-butanol treated or nontreated cells,
and this secretion could be inhibited by the alcohol.
The fact that at low temperature the alcohol induced
an inhibition of the secreted uPA activity, which
disappeared after the alcohol removal, suggests that
in the present conditions, n-butanol may be acting on
another regulatory enzyme. In this regard, PLD must
w xcarry out an enzymatic reaction to produce PB 14 ,
meanwhile the inhibition of PKC by n-butanol occurs
only when the enzyme is positioned in the lipid
w xbilayer 12,17 , where the alcohol can insert itself
w x27 . So, perhaps in these conditions we are being
able to discriminate between n-butanol mediated in-
hibition of PKC and PLD activities in whole cell
assays.
In the presence of n-butanol, PLD activity would
be inhibited resulting in the cellular depletion of
phosphatidic acid, and decreased production of DAG.
There is a strong correlation between the activation
w xof PLD and activation of mitogenesis 28 . Further,
PLD activity has been associated to the regulation of
constitutive or long-lasting cellular events such as
proliferation, cell differentiation and other events like
w xconstitutive secretion 10,28 . Since LM3 tumor cells
w xconstitutively overproduce uPA 20,21 , a PLD-de-
pendent regulation is clearly in accordance with our
model. Phosphatidic acid micelles administered to
LM3 cells increased, in a dose dependent manner, the
production of uPA. This result firmly supports the
hypothesis that PC hydrolysis mediated by PLD ac-
tivity regulates uPA production.
It has been suggested that phosphatidic acid can
w xfunction as a second messenger per se 10,29 . Al-
though the present results do not allow to completely
discard this hypothesis, the fact that propranolol,
described to interact with phosphatidic acid and block
its use as a substrate by PAP, could inhibit the
production of uPA, supports our hypothesis that
phosphatidic acid functions mainly as an intermediate
metabolite for DAG synthesis or maybe other inter-
mediary metabolites such as LPA, in the regulation of
uPA production. This line of evidence suggests that
n-butanol is blocking the endogenous production of
phosphatidic acid and eventually DAG. Phosphatidic
acid can be converted to a variety of intracellular
second messengers that may play an important role in
generating intracellular signals regulating several cel-
w xlular events 10 . Recently it was reported that Raf-1
kinase interacts with phosphatidic acid in vitro and its
translocation to the plasma membrane of MDCK
cells is blocked by the generation of phos-
phatidylethanol, by PLD at the expense of phospha-
w xtidic acid 30 . We are unable to establish which other
mechanisms are functioning in this regulatory point,
but the fact that high doses of phosphatidic acid
inhibited uPA production suggests that phosphatidic
acid-dependent signals may be a central regulatory
point for the expression of this enzyme and other
cellular events.
Since n-butanol can inhibit phosphatidic acid pro-
duction dependent on PLD as well as PKC activity,
we studied the role of PKC in the regulation of uPA
production. It has been extensively described that
phorbol esters, such as PMA, are specific activators
w xof PKC activity 12,31 . Depending on the doses and
time of exposure used in whole cell assays, PMA can
w xalso deplete cells of PKC 31 . PMA has been de-
scribed to exert its effect on the C1 region of PKC
w xregulatory domain 12,31 . It has been elegantly
demonstrated that n-butanol can specifically inhibit
the DAG analogue-mediated activation of PKC in a
competitive manner on a discrete zone of the PKC
w xregulatory domain 12 . On the other hand, n-butanol
inhibition of PKC activity can be partially reversed,
in a dose dependent but not competitive manner, by
w xphorbol esters 17 suggesting two different and dis-
crete sites for PKC activation by both agonists on the
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w xregulatory domain of the protein 12 . Here we
demonstrate that uPA production can be stimulated in
a dose dependent manner by increasing amounts of
the phorbol ester PMA, clearly involving a PKC-de-
pendent mechanism.
If n-butanol would decrease uPA production
through PKC inhibition, the alcohol would modulate
the production of uPA induced by PMA. Our results
demonstrated that PMA-mediated stimulation of uPA
production was partially blocked by n-butanol in a
w xnon competitive manner, as described 17 for iso-
lated enzyme assays. Interestingly, even in the pres-
ence of n-butanol, PMA could significantly enhance
the secreted uPA activity and antigen demonstrating
that PMA could also partially reverse in a dose
dependent way the inhibitory effect of n-butanol on
uPA production. It has been proposed that PKC
activates PLD and that this last enzyme would act, in
a positive feedback loop, on PKC activation by con-
w xstantly producing DAG 13,32 . The capacity of PMA
to reverse the inhibitory effect of n-butanol on uPA
production could be due to the fact that PMA-media-
ted activation could be bypassing the DAG dependent
activation of PKC and also reversing the inhibitory
effect of the alcohol on PKC itself. The fact that high
doses of PMA, known to deplete cells of PKC activ-
w xity 29 , induce a lower but still significant stimula-
tion of uPA secreted activity suggests that during the
period of time used to prepare the conditioned media,
the depletory effects of PMA are functioning. This
probably resulted in a lower secretion or synthetic
activity by tumor cells in the final stages of condi-
tioned media preparation. In addition, when high
doses of PMA were used in the presence of n-butanol
a clear inhibitory effect on the production of uPA
was observed. This result suggests an additive effect
of PMA-depleting activity and n-butanol inhibition
on the remaining membrane activated PKC and prob-
ably on the DAG endogenous production. Thus, to
our knowledge, these results would demonstrate for
the first time that PLD with PAP and PKC could be
clearly a central regulatory point for uPA production
in tumor cells.
w xRecently Reich et al. 33 have demonstrated that
laminin induced expression of metalloproteinase-2
can be blocked by n-butanol, proposing a similar
mechanism for the PLD- dependent regulation of this
protease. However, no association was done with
PKC and the inhibitory effect of n-butanol on this
last enzyme.
H7, an inhibitor of conventional PKCa and atypi-
cal PKCz has been described to interact with the
catalytic domain of PKC and compete with ATP for
w xbinding to the enzyme 25 . Here we demonstrate that
H7 significantly inhibited uPA production, confirm-
ing that PKC activity is indeed involved in the signal-
ing pathway controlling uPA production. However
more information is required in order to know if one
or more isoforms of PKC are involved in the regula-
tion of uPA production.
w xGrowth factors such as EGF, PDGF 31 and extra-
cellular matrix derived components like fibronectin
or laminin usually modulate tumor cell responses
w xboth in vivo and in vitro 38 . It has been previously
demonstrated that primary cultures of M3 tumors
secrete elevated levels of uPA in response to growth
w xfactors such as IGF-I and II 6 . Other authors have
also reported that EGF can stimulate uPA mRNA
w xexpression 5 and other EGF-dependent cellular
w xevents involving the PLD and PKC pathway 39 . In
the present work it is shown that two different murine
mammary tumor cell lines, secrete in a dose depen-
dent manner, high levels of uPA when incubated with
EGF. Interestingly, while even in presence of n-
butanol uPA could be stimulated by the cotreatment
with PMA, the cotreatment with EGF was unable to
reverse the inhibitory effect of n-butanol. Further-
more, when n-butanol treated cells were incubated
with EGF, after n-butanol removal, the growth factor
was unable to stimulate uPA production up to 8 h.
These results suggested that the n-butanol inhibitory
effects on PLD and PKC could be responsible for the
inhibition of EGF-mediated stimulation of uPA pro-
duction. It has been described that EGF exerts its
effect via a tyrosine kinase receptor coupled to the
PLD PC breakdown and PKC signaling pathways
w x11,40 . It could be supposed that since EGF must
activate sequentially all the components of the regula-
tory pathway to stimulate uPA production, the inhibi-
tion of n-butanol on a key reaction of the pathway,
such as PLD-mediated breakdown of PC, would in-
hibit the downstream reactions and finally the pro-
duction of uPA. PMA, unlike EGF, can bypass the
components of the pathway upstream to PKC and
directly activate the enzyme exerting its stimulatory
effect on uPA production.
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The present results raise several interesting and
important questions regarding the mechanism by
which tumor cells govern the signal transduction
pathways modulating the expression of proteolytic
enzymes. It is clear, that the production of proteolytic
enzymes such as uPA in normal tissues is a regulated
w xnon constitutive process 5 . For example endothelial
cells will only produce proteases under determined
w xangiogenic or tissue remodeling stimuli 41 . On the
other hand, it seems a common feature of tumor cells
to enhance or abolish determined signal transduction
pathways or components of these pathways with the
net result of an aberrant intracellular signaling, result-
ing in a high proliferative capacity, diminished adhe-
sion and enhanced production of proteolytic enzymes
w x1,42 . Tumor cells produce, in a constitutive way,
enzymes that were previously under controlled regu-
lation. The key event that makes this occur remains
obscure. It is known that transfection of normal
fibroblasts with Ha-ras can result in transformation
and the acquisition of the invasive phenotype involv-
ing enhanced expression of Ras protein and altered
w xexpression of other regulatory enzymes 42 , although
the components which mediate these events were not
fully described. Here we demonstrate that uPA, a key
proteolytic enzyme, involved in the metastatic cas-
cade and associated with the invasive phenotype, is
under a high constitutive but still regulated control of
the PLD and PKC pathway in LM3 cells. It has also
been reported that MMP expression in tumor cells is
w xcontrolled by a TPA response element 43 or depen-
w xdent of PLD activity 33 , suggesting a common
signaling pathway for regulation. In addition cathep-
sin L is also known to be regulated by a TPA and
w xtyrosine kinase dependent pathways 37 . All these
enzymes are the most described extracellular matrix
degradative components of the metastatic cascade
and some of them have been also used as prognostic
w xindicators 44 . Aberrant regulation of PKC usually
occurs in tumor cells and it is probable that these
alterations which result in the overexpression or sup-
pression of intracellular regulatory components gov-
erning proteolytic enzymes production, must be oc-
w xcurring at the transcriptional level 31,32 . The possi-
bility of other regulatory components participating in
these regulatory events such as mutated or wild type
p21-Ras or ˝-src proteins cannot be discarded. In
this regard, low doses of staurosporine, described to
w xstimulate src phosphorylation 36 and tumor pro-
tease expression through a PKC-independent and ty-
w xrosine kinase-dependent pathway 37 , stimulated uPA
 .production by LM3 cells our unpublished data .
We believe that these results will prove useful for
further research on signaling pathways governing the
metastatic phenotype of tumor cells and for the anti-
w xsignaling or orthosignaling 34,35 therapeutic strate-
w xgies that are being developed at the present time 45 .
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